New apalutamide study opens for prostate cancer

February 14, 2018

A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer:

Experimental arm: apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor, plus degarelix, a hormonal therapy used to reduce testosterone
Experimental arm: apalutamide and degarelix plus abiraterone acetate and prednisone
Control arm: degarelix alone

“Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer,” according to findings from the phase 3 SPARTAN trial reported in OncLive on Feb. 5. The SPARTAN trial, published in the New England Journal of Medicine on Feb. 8, found that “median metastasis-free survival was more than 2 years longer” for men who received apalutamide. Read more in the New York Times.

Brendan Curti, M.D., the principal investigator of the new three-arm study at Providence Cancer Institute, is a medical oncologist and director of genitourinary oncology research at the Earle A. Chiles Research Institute.

See Providence study details here:

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

More prostate cancer studies

This study is one of three clinical trials open to men with prostate cancer at Providence Cancer Institute. See all prostate cancer studies.

To refer patients to any of these studies, call Providence Cancer Institute’s Clinical Research office at 503-215-2614 or visit oregon.providence.org/clinical-trials.

Welcome to your journey for creating a healthier you

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

Most Recent Articles

Providence Queen of the Valley sees 33,894 patients every year in its emergency department. Last year alone, the hospital cared for 598 trauma patients and 285 motor vehicle crashes.

Since 2022, TeleSpiritual Health has been a compassionate lifeline for caregivers offering virtual support available every day of the week from the comfort of their home.

Providence Cancer Institute researchers share important cancer research at SITC annual meeting and receive recognition for their contributions to science.

The Center for Outcomes Research and Education’s Data for Change program provides data tools and training to organizations that serve our community.

Find information and latest updates regarding negotiations at Providence Sacred Heart Medical Center.

Providence St. Mary in Walla Walla, WA, acquires a da Vinci robotic surgical system

PLUVICTO operates like a homing missile that specifically targets PSMA-positive prostate cancer cells.

Thanks to innovative improvements, patients at Providence St. Joseph Hospital Eureka’s Level III Trauma Center are now seen within ten minutes of arrival.

New studies at Providence Cancer Institute offer hope to patients with limited treatment options.

Advanced glycation end-products are compounds that form when sugar binds to protein or fat. This happens naturally as we age but can accelerate with certain health conditions and even the way we cook.

Chris Brinegar is a breast cancer survivor, and hopes his story encourages men to lose the stigma to protect their health. Read his story.

Providence Holy Cross Medical Center announced the opening of its newly expanded cardiac rehab gym designed to help patients safely rebuild their strength and confidence after a cardiac event.

Providence Portland Medical Center was designated as a Magnet organization in 2005, 2010, 2015, 2020 by the ANCC Magnet Recognition Program® and they are now applying for redesignation.

Kadlec Clinic Bridge Care

Holy Cross is the first Providence hospital in the San Fernando Valley to offer bronchoscopic lung volume reduction, a minimally invasive treatment for patients with severe COPD and emphysema.

The NICU at Providence Portland Medical Center won third place in an international reading competition.

Providence Cancer Institute leader joined experts in cancer research, policy and advocacy to discuss current challenges and the future of research.

Doctors at Providence St Jude Medical Center are using advanced methods and state-of-the-art technology to restore vision through laser-assisted cataract surgery.

Improve your heart health with these easy dietary tips focused on balanced nutrition and mindful eating.